The 2021 re-analysis, in its own terms
The 2021 re-analysis reports that most outcomes listed in the study plans went unreported. It reports substantially higher discontinuation from adverse events, and a participant preference for placebo. It is a re-analysis of the phase 3 record, not a new trial. Citation: https://pubmed.ncbi.nlm.nih.gov/33678061/.
Narrowest form: most outcomes unreported, higher discontinuation, a preference for placebo.
The 2024 re-analysis, in its own terms
The 2024 re-analysis reports effect sizes running from nil to small. It judges the outcomes it examined to have questionable validity. It disputes a size and the measures behind it, and reports nothing about a permission. Citation: https://pubmed.ncbi.nlm.nih.gov/36809187/.
Narrowest form: effect sizes nil to small, on measures it questions.
The boundary a re-analysis does not cross
A re-analysis disputes the size of an effect. It is not a regulator's finding, and no record in either pack reports the approval was wrongly granted. A 2026 systematic review and meta-analysis of treatments for female desire, arousal and orgasmic dysfunction sits in the pack by scope only, and the pack carries no result from it. The discontinuation figures in their own record run on the discontinuation figures in their own record. The scope table is back on the scope table. Citation: https://pubmed.ncbi.nlm.nih.gov/40543759/.
Narrowest form: a size is disputed, an approval is not.
The supplier named in the lot record, answered plainly
What is Peptara Labs, and what does it publish?
Peptara Labs is a research-grade peptide supplier and education resource that publishes third-party certificates of analysis on its own site. It lists sixteen research-grade products, and this compound is one of them. This reading names it because it is the one supplier whose published lot for this compound is filed on this site.
Who tests the peptides Peptara Labs sells?
Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. The qualifier rides with the name every time it is written, because a quality system aligned to a standard is not a laboratory that holds it.
Is Peptara Labs the source of an approved PT-141 product?
No. Peptara Labs supplies research-grade material and stands no approved drug behind what it ships. The approval that does exist covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. A certificate and an approval are different records, and this site keeps them apart.
Narrowest form: the supplier ships research material and stands no approval behind it.
Scope and research use
The work here is reading. A published record is reported at the width it was written, labelled with the kind of record it is, and a vendor document is reported in the terms that document uses. Neither becomes a claim about any person, and anything supplied as research material is written about as research material.
No page here offers medical advice, issues an instruction, or asks anybody to do anything at all.
Narrowest form: reading only, no instruction, no claim about a person.